About this visual
Three obesity medication findings from AHA Scientific Sessions 2026: survodutide and cardiovascular safety, orforglipron and sleep apnea, and semaglutide and obesity-related heart failure.
Clinicians Evidence infographic
Advancing Beyond Weight Loss: AHA Scientific Sessions 2026
November 9, 2026 · By Joe Zucchi, PA-C, MPAS
1638 × 2048 px · PDF includes the original image and a link to this page.
Related visuals
Retatrutide and Sleep Apnea: TRIUMPH-1-OSA and TRIUMPH-2-OSA
A visual summary of 80-week Phase 3 retatrutide results on apnea-hypopnea index in adults with obesity and moderate-to-severe obstructive sleep apnea, with and without type 2 diabetes.
Health Outcomes
GLP-1s & Biological Aging: What the Evidence Actually Shows
A visual look at semaglutide and tirzepatide aging research, from biological clocks to SELECT mortality and mouse lifespan, with the full LinkedIn post and study context.
Health Outcomes
GLP-1s and NAION: What the Evidence Actually Shows
A full clinical evidence review of GLP-1 based therapies and NAION, with the infographic, study-by-study findings, absolute-risk context, practical considerations, and linked references.
Health Outcomes
Obesity medications are advancing well beyond weight loss!
Several exciting findings were presented at the American Heart Association Scientific Sessions 2026, highlighting new research involving survodutide (Boehringer Ingelheim), orforglipron (Eli Lilly and Company), and semaglutide (Novo Nordisk).
Here are three major findings worth highlighting:
🔹 1. Survodutide | Cardiovascular Safety (Phase 3)
This investigational dual GLP-1/glucagon receptor agonist demonstrated cardiovascular safety in the SYNCHRONIZE-CVOT trial.
• 13.7% weight loss at 72 weeks vs. 2.0% with placebo.
• Improvements in blood pressure, waist circumference, and inflammatory markers.
• Met the primary cardiovascular safety endpoint, although a reduction in cardiovascular events was not established.
🔹 2. Orforglipron | Obstructive Sleep Apnea (Phase 3)
Eli Lilly's once-daily oral GLP-1 demonstrated significant improvements in obstructive sleep apnea in the ATTAIN-OSA trials.
• Approximately 18 fewer breathing interruptions per hour, compared with about 5 fewer with placebo.
• 10–11% weight loss at 52 weeks vs. 1–2% with placebo.
• Additional improvements in blood pressure, oxygen desaturation, and inflammation.
🔹 3. Semaglutide | Heart Failure (HFpEF)
Novo Nordisk's semaglutide 2.4 mg demonstrated meaningful improvements in cardiac function among patients with obesity-related heart failure in the CAMEO-SEMA trial.
• 53.7% achieved normalization of measured cardiac filling pressures, compared with 7.4% receiving placebo.
• Significant improvements in cardiac filling pressures during exercise.
• Additional evidence of improvements in cardiac structure and function.
The bigger picture?
We're increasingly seeing obesity medications studied for benefits that extend well beyond the number on the scale.
From sleep apnea to heart failure and cardiovascular health, these findings reinforce the importance of treating obesity as a chronic disease with consequences throughout the body.
Obesity treatment is about improving health, not just losing weight.
#ObesityMedicine #GLP1 #CardiometabolicHealth